In a new report on vaccine pricing, MSF says British company GlaxoSmithKline(GSK) and US giant Pfizer should slash the price of the vaccines to $5 (£3.20) per child in developing countries....“We have an irrational situation where some developing countries like Morocco and Tunisia are paying more for the pneumococcal vaccine than France does,” said Kate Elder, vaccines policy adviser for MSF’s Access Campaign....GSK and Pfizer have collectively reported more than $19bn in global sales of the vaccine since it launched...GSK said its pneumococcal vaccine is “one of the most complex we’ve ever manufactured, essentially combining 10 vaccines in one”. It added: “For Gavi-eligible countries, we are providing this vaccine at a deeply discounted price. At this level, we are able to just cover our costs. To discount it further would threaten our ability to supply it to these countries in the long-term. Nevertheless, we continue to look at ways to reduce production costs and any savings we make we would pass on to Gavi.”  Pfizer said 60% of the world’s poor children are covered by the Gavi programme at a price that is “far below” the cost to manufacture the vaccine.